ClinicalTrials.gg
CompletedNCT03422068Updated Nov 28, 2025Results posted

This Study Tests Different Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF). The Study Tests How BI 1015550 is Taken up by the Body and How Well it is Tolerated.

A Phase 1 interventional study of BI 1015550 and Placebo in Idiopathic Pulmonary Fibrosis, sponsored by Boehringer Ingelheim. Completed at 11 sites in 7 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-11-28.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim — 1 open to participants now, 3 under way, 1 of them phase 3. Idiopathic Pulmonary Fibrosis · Boehringer Ingelheim.

Enrollment
18th of 18
15 · median 109
Started
2018
with 2 others
Phase 1
Only one
of the 36
Registered
16th of 36
by date

Among the 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim, this one is the 18th largest by enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2018, is the only one in phase 1, and was the 16th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

1 of the 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim is open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim, or all of them as a file.
02

Study summary

The primary objective is to investigate safety and tolerability of BI 1015550 in patients with IPF.

The secondary objectives are to evaluate the pharmacokinetics (PK) of BI 1015550 in patients with IPF.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated written prior to admission to the study in accordance with ICH Harmonised Tripartite Guideline for Good Clinical Practice (ICH-GCP) and local legislation
  • Male or female patients aged ≥40 years at visit 1.
  • A clinical diagnosis of IPF based on ATS/ERS/JRS/ALAT 2011 guideline within the previous 5 years as confirmed by the investigator based on chest high-resolution computed tomography (HRCT) scan taken within 12 months of visit 1 and confirmed by central review prior to visit 2.
  • Forced Vital Capacity (FVC) ≥50% of predicted normal at visit 1
  • Diffusion capacity of the lung for carbon monoxide (DLCO) (corrected for [Hb] [Visit 1]): > 30% of predicted normal at visit 1

Exclusion criteria

Exclusion Criteria:

  • Patients with a significant disease or condition other than IPF which in the opinion of the investigator, may put the patient at risk because of participation, interfere with study procedures, or cause concern regarding the patient's ability to participate in the study.
  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  • Surgery of the GI tract that could interfere with PK of the trial medication (except appendectomy)
  • Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders including but not limited to mood disorders.
  • Evidence of active infection (chronic or acute) based on clinical exam or laboratory findings.
  • History of allergy or to the trial medication or its
  • Use of drugs within 30 days prior to administration of trial medication that are known to influence the results of the trial including time between start of the Q-wave and the end of the T-wave in an () / QT interval corrected for heart rate using the method of Fridericia (QTcF) or Bazett (QTcB) (QTc)
  • A marked baseline prolongation of QT/QTc interval (such as QTc intervals that are repeatedly greater than 450 ms in males or repeatedly greater than 470 ms in females) or any other relevant ECG finding at screening
  • A history of additional risk factors for Torsades de Pointes (such as heart failure, hypokalemia, or family history of Long QT Syndrome)
  • Participation in another trial where an drug has been administered within 30 days or less than 5 half-lives (whichever is greater) of the respective drug prior to planned administration of trial medication, or current participation in another trial involving administration of investigational drug.
  • Inability to refrain from smoking on trial days
  • Alcohol abuse (consumption of more than 20 g per day)
  • Active drug abuse
  • Blood donation of more than 100 mL within 30 days prior to administration of trial medication or intended donation during the trial
  • Inability to comply with dietary regimen required for the trial
  • Patient is assessed as unsuitable for inclusion by the investigator, for instance, because considered not able to understand and comply with study requirements, or has a condition that would not allow safe participation in the study
  • Male patients who do not agree to minimize the risk of female partners becoming pregnant from first dosing day until two months after the study completion. Acceptable methods of comprises barrier contraception and a medically accepted contraceptive method for the female partner (intra-uterine device with spermicide, hormonal contraceptive used for at least two months prior), true sexual abstinence (when this is in line with the preferred and usual lifestyle of the patient), or surgically sterilized, including vasectomy.
  • Females who are not surgically sterilised or who are not , defined as at least 1 year of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous levels of Follicle-stimulating hormone (FSH) above 40 U/L and estradiol below 30 ng/L is confirmatory).
  • Relevant airways obstruction (i.e. pre-bronchodilator /FVC \<0.7) at visit 1
  • Patients who have previously been treated with nintedanib or pirfenidone within 30 days of visit 1.
  • Positive fecal occult blood (no retest allowed),
  • Positive testing for hematuria if confirmed by microscopic urine analysis (retest allowed)
  • Any lifetime history of suicidal behavior (i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behavior)
  • Any suicidal ideation of type 2 to 5 on the C-SSRS in the past 12 months (i.e. active suicidal thought without method, intent or plan; active suicidal thought with method, but without intent or plan; active suicidal thought with method and intent but without specific plan; or active suicidal thought with method, intent and plan).
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    18 mg BI 1015550

    3 tablets of 6 milligram (mg) of BI 101550 (total: 18 mg) were administrated as an oral dose together with about 240 milliliter (mL) of water twice daily (bid). Treatment period was 4 weeks for patients entered after approval of a global protocol amendment 3 at 12 Feb 2019 or 12 weeks for those entered before approval.

    Drug: BI 1015550

  • Placebo comparator
    Placebo

    3 tablets of Placebo, matching in size and weight to BI 1015550 6 milligram (mg) tablet, were administrated as an oral dose together with about 240 milliliter (mL) of water twice daily. Treatment period was 4 weeks for patients entered after approval of a global protocol amendment 3 at 12 Feb 2019 or 12 weeks for those entered before approval.

    Drug: Placebo

Interventions

  • 3 tablets of 6 milligram (mg) of BI 101550 (total: 18 mg) were administrated as an oral dose together with about 240 milliliter (mL) of water twice daily (bid).

    Also known as: Nerandomilast, JASCAYD®

  • DrugPlacebo

    3 tablets of Placebo, matching in size and weight to BI 1015550 6 milligram (mg) tablet, were administrated as an oral dose together with about 240 milliliter (mL) of water twice daily.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Drug-related Adverse Events (AEs) On-treatment

    The analysis of AEs was based on the concept of treatment-emergent AEs (TEAEs). All AEs which occurred through the treatment phase and throughout the residual effect period (REP) were considered as on treatment. Treatment period was 4 weeks for patients entered after approval of a global protocol amendment at 12 Feb 2019 or 12 weeks for those entered before approval.

    Time frame: From first dose until last dose of treatment period (duration depends on the time a patient entered the trial) + 7 days of REP or until patient's trial termination date, whichever occurred earlier, up to 35 or 91 days.

Secondary outcomes

  1. Area Under the Concentration-time Curve (AUCτ,1) of the BI 1015550 in Plasma Over a Uniform Dosing Interval τ After Administration of the First Dose on Day 1

    Area under the concentration-time curve (AUCτ,1) of the BI 1015550 in plasma over a uniform dosing interval τ after administration of the first dose on Day 1.

    Time frame: On Day 1, within 2 hours before morning dose and at 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours after morning dose.

  2. Maximum Measured Concentration (Cmax) of the BI 1015550 in Plasma on Day 1

    Maximum measured concentration (Cmax) of the BI 1015550 in plasma on Day 1.

    Time frame: On Day 1, within 2 hours before morning dose and at 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours after morning dose.

  3. Area Under the Concentration-time Curve (AUCτ,ss) of the BI 1015550 in Plasma at Steady State Over a Uniform Dosing Interval τ on Day 14

    Area under the concentration-time curve (AUCτ,ss) of the BI 1015550 in plasma at steady state over a uniform dosing interval τ on Day 14.

    Time frame: On Day 14, within 2 hours before morning dose and at 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours after morning dose.

  4. Maximum Measured Concentration (Cmax,ss) of the BI 1015550 in Plasma at Steady State Over a Uniform Dosing Interval τ on Day 14

    Maximum measured concentration (Cmax,ss) of the BI 1015550 in plasma at steady state over a uniform dosing interval τ on Day 14.

    Time frame: On Day 14, within 2 hours before morning dose and at 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours after morning dose.

07

Results

Posted Nov 28, 2025
Limitations and caveats
The trial was halted after the first dose group (18 milligram (mg) of BI 1015550 twice daily (bid)) as the predicted gMean (based on pharmacokinetic modelling) for the next higher dosage group (24mg bid) exceeded the predefined exposure threshold.

Participant flow

This randomized, double-blind, placebo-controlled, multiple rising dose trial was to test safety and tolerability of BI 1015550 in patients with idiopathic pulmonary fibrosis under dosage of 18mg and 24mg twice daily (bid). Dose escalation was stopped after the 18 mg bid dose group as predefined stopping criteria was met.

Participant flow — Overall Study
MilestonePlacebo18 mg BI 1015550
Started510
Completed58
Not completed02
Withdrew: Adverse event01
Withdrew: Inconvenience to frequent study visits01

Outcome measures

PrimaryPercentage of Participants With Drug-related Adverse Events (AEs) On-treatment

The analysis of AEs was based on the concept of treatment-emergent AEs (TEAEs). All AEs which occurred through the treatment phase and throughout the residual effect period (REP) were considered as on treatment. Treatment period was 4 weeks for patients entered after approval of a global protocol amendment at 12 Feb 2019 or 12 weeks for those entered before approval.

Time frame:
From first dose until last dose of treatment period (duration depends on the time a patient entered the trial) + 7 days of REP or until patient's trial termination date, whichever occurred earlier, up to 35 or 91 days.
Reported as:
Number · Percentage of participants
Percentage of Participants With Drug-related Adverse Events (AEs) On-treatment
Percentage of participants18 mg BI 1015550Placebo
Percentage of Participants With Drug-related Adverse Events (AEs) On-treatment90.060.0
SecondaryArea Under the Concentration-time Curve (AUCτ,1) of the BI 1015550 in Plasma Over a Uniform Dosing Interval τ After Administration of the First Dose on Day 1

Area under the concentration-time curve (AUCτ,1) of the BI 1015550 in plasma over a uniform dosing interval τ after administration of the first dose on Day 1.

Time frame:
On Day 1, within 2 hours before morning dose and at 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours after morning dose.
Reported as:
Geometric mean · nanomol (nmol) * hours (h) / Litre (L)
Area Under the Concentration-time Curve (AUCτ,1) of the BI 1015550 in Plasma Over a Uniform Dosing Interval τ After Administration of the First Dose on Day 1
nanomol (nmol) * hours (h) / Litre (L)18 mg BI 1015550
Area Under the Concentration-time Curve (AUCτ,1) of the BI 1015550 in Plasma Over a Uniform Dosing Interval τ After Administration of the First Dose on Day 11990 ± 18.2
SecondaryMaximum Measured Concentration (Cmax) of the BI 1015550 in Plasma on Day 1

Maximum measured concentration (Cmax) of the BI 1015550 in plasma on Day 1.

Time frame:
On Day 1, within 2 hours before morning dose and at 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours after morning dose.
Reported as:
Geometric mean · nanomol (nmol) / Litre (L)
Maximum Measured Concentration (Cmax) of the BI 1015550 in Plasma on Day 1
nanomol (nmol) / Litre (L)18 mg BI 1015550
Maximum Measured Concentration (Cmax) of the BI 1015550 in Plasma on Day 1277 ± 23.1
SecondaryArea Under the Concentration-time Curve (AUCτ,ss) of the BI 1015550 in Plasma at Steady State Over a Uniform Dosing Interval τ on Day 14

Area under the concentration-time curve (AUCτ,ss) of the BI 1015550 in plasma at steady state over a uniform dosing interval τ on Day 14.

Time frame:
On Day 14, within 2 hours before morning dose and at 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours after morning dose.
Reported as:
Geometric mean · nanomol (nmol) * hours (h) / Litre (L)
Area Under the Concentration-time Curve (AUCτ,ss) of the BI 1015550 in Plasma at Steady State Over a Uniform Dosing Interval τ on Day 14
nanomol (nmol) * hours (h) / Litre (L)18 mg BI 1015550
Area Under the Concentration-time Curve (AUCτ,ss) of the BI 1015550 in Plasma at Steady State Over a Uniform Dosing Interval τ on Day 143720 ± 49.5
SecondaryMaximum Measured Concentration (Cmax,ss) of the BI 1015550 in Plasma at Steady State Over a Uniform Dosing Interval τ on Day 14

Maximum measured concentration (Cmax,ss) of the BI 1015550 in plasma at steady state over a uniform dosing interval τ on Day 14.

Time frame:
On Day 14, within 2 hours before morning dose and at 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours after morning dose.
Reported as:
Geometric mean · nanomol (nmol) / Litre (L)
Maximum Measured Concentration (Cmax,ss) of the BI 1015550 in Plasma at Steady State Over a Uniform Dosing Interval τ on Day 14
nanomol (nmol) / Litre (L)18 mg BI 1015550
Maximum Measured Concentration (Cmax,ss) of the BI 1015550 in Plasma at Steady State Over a Uniform Dosing Interval τ on Day 14460 ± 41.7

Adverse events

Collected over From first dose until last dose of treatment period (duration depends on the time a patient entered the trial) + 7 days of REP or until patient's trial termination date, whichever occurred earlier, up to 35 or 91 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/5 (0%)0/5 (0%)5/5 (100%)
18 mg BI 10155500/10 (0%)1/10 (10%)10/10 (100%)
Most frequent serious events
Most frequent serious events
EventPlacebo18 mg BI 1015550
Anal fistulaGastrointestinal disorders0/51/10
Anal incontinenceGastrointestinal disorders0/51/10
Most frequent other events
Showing 10 of 35
Most frequent other events
EventPlacebo18 mg BI 1015550
DiarrhoeaGastrointestinal disorders2/54/10
NasopharyngitisInfections and infestations0/54/10
FlatulenceGastrointestinal disorders1/53/10
Occult blood positiveInvestigations1/53/10
Vision blurredEye disorders1/50/10
FatigueGeneral disorders1/52/10
PharyngitisInfections and infestations1/50/10
Respiratory tract infectionInfections and infestations1/50/10
Muscle spasmsMusculoskeletal and connective tissue disorders0/52/10
Muscle tightnessMusculoskeletal and connective tissue disorders0/52/10

Baseline characteristics

Treated set (TS): This patient set included all patients who received at least one dose of study drug. It was used for the analysis of safety, demographic data, and baseline characteristics.

Age, Continuous
Age, Continuous(Years)Placebo18 mg BI 1015550Total
Mean70.2 ± 3.369.5 ± 10.169.7 ± 8.3
Sex: Female, Male
Sex: Female, Male(Participants)Placebo18 mg BI 1015550Total
Female112
Male4913
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo18 mg BI 1015550Total
Hispanic or Latino000
Not Hispanic or Latino51015
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo18 mg BI 1015550Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White51015
More than one race000
Unknown or Not Reported000
08

Study locations

11 sites
  • Odense University Hospital
    Odense, 5000 C, Denmark
  • HYKS Keuhkosairauksien tutkimusyksikkö
    Helsinki, 00290, Finland
  • TYKS
    Turku, 20520, Finland
  • Fraunhofer ITEM
    Hanover, 30625, Germany
  • Universitätsklinikum Heidelberg
    Heidelberg, 69126, Germany
  • Poli Univ A. Gemelli
    Roma, 00168, Italy
  • St. Antonius ziekenhuis, locatie Nieuwegein
    Nieuwegein, 3435 CM, Netherlands
  • Erasmus Medisch Centrum
    Rotterdam, 3015 CE, Netherlands
  • Hospital de Bellvitge
    L'Hospitalet de Llobregat, 08907, Spain
  • Royal Brompton Hospital
    London, SW3 6NP, United Kingdom
  • Southampton General Hospital
    Southampton, SO16 6YD, United Kingdom
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Jul 2019, 15 months.

Results were first posted in Nov 2025, 6 years 4 months after primary completion.

Of 60 industry-sponsored phase 1 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 15 months is above that.

Counting every sponsor, half of 75 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2018
First posted
Feb 5, 2018
StartActual
Mar 16, 2018
Primary completionActual
Jul 1, 2019
CompletionActual
Jul 10, 2019
Results first posted
Nov 28, 2025
Last update
Nov 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03422068
Responsible party
Sponsor
First posted
Feb 5, 2018
Start date
Mar 16, 2018
Primary completion
Jul 1, 2019
Completion
Jul 10, 2019
Results posted
Nov 28, 2025
Last update
Nov 28, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nerandomilast

Start the discussion